Flumazenil-Insensitive Benzodiazepine Effects in Recombinant αβ and Neuronal GABAA Receptors. 2020

Jing-Jing Lian, and Yan-Qing Cao, and Yu-Lei Li, and Gang Yu, and Rui-Bin Su
State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Key Laboratory of Neuropsychopharmacology, Beijing Institute of Pharmacology and Toxicology, 27th Taiping Road, Beijing 100850, China.

Gamma-aminobutyric acid, type A (GABAA) receptors are complex heterogeneous pentamers with various drug binding sites. Several lines of evidence suggest that benzodiazepines modulate certain GABAA receptors in a flumazenil-insensitive manner, possibly via binding sites other than the classical ones. However, GABAA receptor subtypes that contain non-classical benzodiazepine binding sites are not systemically studied. The present study investigated the high-concentration effects of three benzodiazepines and their sensitivity to flumazenil on different recombinant (α1β2, α2β2, α3β2, α4β2, α5β2 and α1β3) and native neuronal GABAA receptors using the whole-cell patch-clamp electrophysiology technique. The classical benzodiazepine diazepam (200 μmol/L) and midazolam (200 μmol/L) produced flumazenil-insensitive effects on α1β2 receptor, whereas the imidazopyridine zolpidem failed to modulate the receptor. Flumazenil-insensitive effects of diazepam were also observed on the α2β2, α3β2 and α5β2, but not α4β2 receptors. Unlike β2-containing receptors, the α1β3 receptor was insensitive to diazepam. Moreover, the diazepam (200 μmol/L) effects on some cortical neurons could not be fully antagonized by flumazenil (200 μmol/L). These findings suggested that the non-classical (flumazenil-insensitive) benzodiazepine effects depended on certain receptor subtypes and benzodiazepine structures and may be important for designing of subtype- or binding site- specific drugs.

UI MeSH Term Description Entries

Related Publications

Jing-Jing Lian, and Yan-Qing Cao, and Yu-Lei Li, and Gang Yu, and Rui-Bin Su
December 2019, Life sciences,
Jing-Jing Lian, and Yan-Qing Cao, and Yu-Lei Li, and Gang Yu, and Rui-Bin Su
January 1996, Neuropharmacology,
Jing-Jing Lian, and Yan-Qing Cao, and Yu-Lei Li, and Gang Yu, and Rui-Bin Su
July 1990, Neuroscience letters,
Jing-Jing Lian, and Yan-Qing Cao, and Yu-Lei Li, and Gang Yu, and Rui-Bin Su
August 2018, ACS chemical biology,
Jing-Jing Lian, and Yan-Qing Cao, and Yu-Lei Li, and Gang Yu, and Rui-Bin Su
February 1995, Epilepsia,
Jing-Jing Lian, and Yan-Qing Cao, and Yu-Lei Li, and Gang Yu, and Rui-Bin Su
July 2020, Progress in neuro-psychopharmacology & biological psychiatry,
Jing-Jing Lian, and Yan-Qing Cao, and Yu-Lei Li, and Gang Yu, and Rui-Bin Su
May 1999, The Journal of physiology,
Jing-Jing Lian, and Yan-Qing Cao, and Yu-Lei Li, and Gang Yu, and Rui-Bin Su
October 1989, Trends in pharmacological sciences,
Jing-Jing Lian, and Yan-Qing Cao, and Yu-Lei Li, and Gang Yu, and Rui-Bin Su
February 1991, Biochemical Society transactions,
Copied contents to your clipboard!